Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bioxcel Therapeutics Inc.

3.55
+0.18005.34%
Volume:578.43K
Turnover:2.10M
Market Cap:12.05M
PE:-0.11
High:3.85
Open:3.27
Low:3.27
Close:3.37
Loading ...

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia

GlobeNewswire
·
12 Nov 2024

Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know

Zacks
·
05 Nov 2024

BioXcel announces defense grant to UNC to fund study for treating acute stress disorder

seekingalpha
·
15 Oct 2024

BRIEF-BioXcel Therapeutics Says Phase 2A Trial Enrollment Expected In H1 2025

Reuters
·
15 Oct 2024

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of Bxcl501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

THOMSON REUTERS
·
15 Oct 2024

BioXcel Therapeutics Inc - Dod Awards $2.8 Million to Unc for Bxcl501 Trial

THOMSON REUTERS
·
15 Oct 2024

BioXcel Therapeutics Inc - Phase 2a Trial Enrollment Expected in H1 2025

THOMSON REUTERS
·
15 Oct 2024

Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
25 Sep 2024

BRIEF-Bioxcel Therapeutics Plans To Reduce Workforce By 15 Employees

Reuters
·
19 Sep 2024

BioXcel Therapeutics - Sees Majority of Costs to Be Incurred, Clinical Prioritization Is Expected to Be Completed, During Qtr Ending December 31

THOMSON REUTERS
·
19 Sep 2024

BioXcel Therapeutics: Plan to Reduce Workforce to Extend Its Cash Runway, Prioritize Investment on Clinical Development of Its Bxcl501

THOMSON REUTERS
·
19 Sep 2024

BioXcel Therapeutics Inc - Estimates It Will Incur Aggregate Charges in Connection With Clinical Prioritization of About $1.4 Mln

THOMSON REUTERS
·
19 Sep 2024

BioXcel Therapeutics Announces Clinical Prioritization and Update on Bxcl501 Late-Stage Programs for Agitation

THOMSON REUTERS
·
19 Sep 2024